Professor Mark Sulkowski, M.D.
Johns Hopkins University School of Medicine, Baltimore, USA
Mark Sulkowski, MD, is a Professor of Medicine, the Senior Associate Dean for Clinical Trials, and the Founding Director of the Office of Clinical Trials at the Johns Hopkins University School of Medicine. He also serves as the Director of the Division of Infectious Diseases at the Johns Hopkins Bayview Medical Center and the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine. He received his MD from Temple University School of Medicine, Philadelphia, PA, pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC, and completed his Fellowship in Infectious Diseases at the Johns Hopkins University School of Medicine.
Prof. Sulkowski has been the principal investigator for more than 150 clinical trials on managing viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded ACTG (Advancing Clinical Therapeutics Globally) Network where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation and the American Association of Physicians.
Prof. Sulkowski is a member of numerous professional societies, including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 325 peer-reviewed articles, he is widely published with works in the Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018, 2019, 2020, 2021, and 2022, he was named a Highly Cited Researcher (Clarivate Analytics), defined as being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.